Health News Archive - April 19, 2009
-- Data presented at 100th Annual Meeting of the American Association for Cancer Research -- SEATTLE and DENVER, April 19 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN) presented today data from its PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE(R) (sipuleucel-T) induces long-term memory immune responses that are durable and can be maintained following boosting.
Finally some promising news about pancreatic cancer, one of the most fatal cancers, due to the difficulties of early detection and the lack of effective therapies
The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment
An herb recently found to kill pancreatic cancer cells also appears to inhibit development of pancreatic cancer as a result of its anti-inflammatory properties, according to researchers from the Kimmel Cancer Center at Jefferson.
The Department of Veterans Affairs reported Friday that three patients exposed to contaminated medical equipment have tested positive for HIV.
Men and women who chewed ExtraÂ® sugar-free gum three times hourly in the afternoon chose and consumed less snacks and specifically, less sweet snacks than they did when they did not chew gum.
The good nutrition news is that children in poor, rural parts of the Lower Mississippi Delta are a lot more willing to try fresh fruits and vegetables than generally believed, even by their parents or the kids themselves.
When things go right, transplanted healthy liver cells transplanted by infusion or injection will find their way to the liver, integrate into the damaged tissue
Dr. Nicolas Bazan, Director of the Neuroscience Center of Excellence, Boyd Professor, and Ernest C. and Yvette C. Villere Chair of Retinal Degenerative Diseases Research at LSU Health Sciences Center New Orleans,
- Data Show Fleximer(R) Extends Exposure to Conjugated Drug - CAMBRIDGE, Mass., April 19 /PRNewswire/ -- Mersana, a platform-based cancer therapeutics company, today announced positive results of preclinical studies for its second development candidate, XMT-1107, in two posters at the 2009 Annual Meeting of the American Association of Cancer Research (AACR) in Denver.